Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Cutaneous melanoma is a malignant tumor often driven by BRAF or NRAS mutations, activating the MEK/ERK MAPK pathway.
• MAPK pathway inhibitors are effective for BRAF-mutant melanoma, but NRAS-mutant melanoma exhibits resistance.
• NRAS-mutant melanoma lacks targetable BRAF mutations and shows intrinsic/acquired resistance to MEK inhibition.

Purpose of the Study:

• To investigate if concomitant inhibition of ERK5 can sensitize NRAS-mutant melanoma to MAPK pathway-targeting therapy.
• To identify mechanisms of resistance to MEK inhibition in NRAS-mutant melanoma.
• To evaluate MEK/ERK5 co-inhibition as a potential therapeutic strategy.

Main Methods:

• Utilized approved MEK inhibitors and a pharmacologic ERK inhibitor.
• Analyzed MAPK inhibition-induced ERK5 activation in NRAS-mutant melanoma cells.
• Assessed the correlation between ERK5 phosphorylation, KLF2 nuclear localization, and cell proliferation.
• Tested MEK/ERK5 co-inhibition in vitro and in a xenotransplant mouse model.

Main Results:

• MAPK inhibition triggers delayed ERK5 activation via a PDGFR inhibitor-sensitive pathway in NRAS-mutant melanoma.
• ERK5 phosphorylation and nuclear KLF2 localization are naturally observed in NRAS-mutant melanoma.
• Combined MEK/ERK5 inhibition suppressed long-term growth of human NRAS-mutant melanoma cells in vitro.
• MEK/ERK5 co-inhibition effectively repressed tumor progression in a mouse xenotransplant model.

Conclusions:

• Concomitant inhibition of ERK5 overcomes resistance to MEK inhibitors in NRAS-mutant melanoma.
• MEK/ERK5 co-targeting represents a promising therapeutic approach for NRAS-mutant melanoma.
• This strategy addresses a critical unmet need for targeted therapies in NRAS-mutant melanoma.